ENGNW Company Profile and Key Details

enGene Holdings Inc. Warrants earnings surprise history is a mixed track record. The quarter that ended March 09, 2026, missed forecasts by -21.37%. The prior quarter beat by -578.04%. Over the last six quarters, Apple has recorded several small beats. These include 31.29% in March 10, 2025.

Average 10-day trading volume of 11.17 thousand shares is below the 3-month average of 14.03 thousand, indicating normal recent market interest.

enGene Holdings Inc. Warrants last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.36. This means the shares are trading below this model’s fair value.

enGene Holdings Inc. Warrants (NASDAQ:ENGNW) closed at $0.27 USD, gaining $0.02 (6.00%) from the previous close of $0.25. The stock is currently mid-range between its 52-week high and low $0.25 and $2.10. With a market capitalization of about $13.57 million, enGene Holdings Inc. Warrants is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.29). Key stats such as the average daily volume over the past year has been around 12.97 thousand shares, trading with heavier-than-usual volume. Headquartered in Montreal, QC, enGene Holdings Inc. Warrants operates in the Healthcare sector and the Biotechnology industry. Led by CEO Ronald H. W. Cooper, the company employs approximately 56 people and listed since February 01, 2022. EnGene Holdings Inc., through its enGene, Inc. subsidiary, is a clinical-stage biotechnology company dedicated to advancing genetic medicines.

Valuation shows enGene Holdings Inc. Warrants trading at a premium to the broader market with a P/E of -0.91.

Our AI price prediction model suggests that enGene Holdings Inc. Warrants stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

enGene Holdings Inc. Warrants trades at a P/E ratio of -0.91, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.39 suggesting the stock is closer to book value. The P/FCF stands at -0.81, also above market averages.